raloxifene hydrochloride has been researched along with Arthritis, Rheumatoid in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Esmaily, H; Mehrnaz Aghili, S; Saeidi, S; Sahebari, M; Salari, M; Sarafraz Yazdi, M | 1 |
| Baggott, JE; Morgan, SL | 1 |
| Karahan, S; Keskin, D; Kurum, B; Ocal, Y; Ozen, S; Tezcaner, A | 1 |
| Furuya, T | 1 |
| Jouyama, K; Matoba, K; Mokuda, S; Okuda, Y; Onishi, M; Sawada, N; Takasugi, K; Yamada, A | 1 |
| Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N | 1 |
| Cerinic, MM; Cinelli, M; Del Rosso, A; Del Rosso, M; Fibbi, G; Gabrielli, A; Giacomelli, R; Guiducci, S; Iori, N; Livi, R; Perfetto, F; Rossi, A | 1 |
| Schein, JR; Sewell, K | 1 |
2 review(s) available for raloxifene hydrochloride and Arthritis, Rheumatoid
| Article | Year |
|---|---|
[Bone and calcium metabolism in patients with rheumatoid arthritis].
Topics: Animals; Arthritis, Rheumatoid; Bone and Bones; Calcium; Disease Models, Animal; Disease Progression; Estrogen Replacement Therapy; Estrogens; Female; Humans; Inflammation Mediators; Joints; Male; Menopause; Osteoporosis; Pregnancy; Pregnancy Complications; Raloxifene Hydrochloride | 2011 |
Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Estrogen Replacement Therapy; Female; Gastrointestinal Diseases; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors | 2001 |
1 trial(s) available for raloxifene hydrochloride and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial.
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride | 2023 |
5 other study(ies) available for raloxifene hydrochloride and Arthritis, Rheumatoid
| Article | Year |
|---|---|
The importance of inhibition of a catabolic pathway of methotrexate metabolism in its efficacy for rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Female; Folic Acid; Folic Acid Antagonists; Humans; Leucovorin; Male; Methotrexate; Osteoporosis; Purines; Raloxifene Hydrochloride; Rats; Rats, Inbred Lew; Treatment Outcome | 2019 |
Characterization and evaluation of triamcinolone, raloxifene, and their dual-loaded microspheres as prospective local treatment system in rheumatic rat joints.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Density Conservation Agents; Cell Line; Delayed-Action Preparations; Injections, Intra-Articular; Knee Joint; Microspheres; Polyesters; Raloxifene Hydrochloride; Rats; Triamcinolone | 2014 |
Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Glucocorticoids; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Severity of Illness Index; Vitamin K Deficiency | 2012 |
Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment.
Topics: Arthritis, Rheumatoid; Case-Control Studies; Etidronic Acid; Female; Humans; Kynurenine; Methotrexate; Neopterin; Osteoporosis; Prednisolone; Raloxifene Hydrochloride; Receptors, Glutamate; Tryptophan | 2003 |
Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cell Movement; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Knee Joint; Male; Plasminogen Activator Inhibitor 1; Raloxifene Hydrochloride; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Selective Estrogen Receptor Modulators; Synovial Membrane; Urokinase-Type Plasminogen Activator | 2005 |